[{"id":"8e333d31-cdb1-4edd-a209-db63d88f24e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087263","created_at":"2023-10-17T15:12:53.355Z","updated_at":"2025-02-25T17:26:29.076Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","source_id_and_acronym":"NCT06087263","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SDHB","pipe":" | ","alterations":" KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/18/2024","start_date":" 06/18/2024","primary_txt":" Primary completion: 07/01/2032","primary_completion_date":" 07/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2025-01-10"}]